Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2001

View Archived Issues

Sterix raises funds for R&D programs

Human growth hormone peptide analogue under active development for obesity

Copper/zinc chelator may address underlying cause of Alzheimer's disease

AstraZeneca selects tradename for investigational anticoagulant

Mechanism of blood pressure-lowering effects of PPARgamma agonists studied using GW-1929

BioMarin files application to conduct human trials with topical Vibriolysin

Amgen launches ARANESP in the E.U.

Beneficial effects of insulin sensitizer on lipoprotein abnormalities in db/db mice

Ligand and TAP establish R&D alliance for SARMs

EntreMed and NEI study Panzem in age-related macular degeneration

Efficacy and safety of COL-1621 demonstrated in men with testosterone deficiency

Zycos and Aventis Pasteur extend drug discovery alliance

Medarex and Epicyte to codevelop therapeutic antibodies

New GH receptor antagonist may have a role in the management of colon cancer

Phase I/II trial begins for malignant melanoma vaccine

NicOx and Biolipox to codevelop NO-releasing respiratory therapies

New, orally active PTP1B inhibitor lowers plasma glucose and insulin levels in ob/ob mice

Phase I/II bladder cancer trial shows 59% complete response rate on MCC therapy

International Psoriasis Symposium selected by MedImmune to present phase I results for MEDI-507

Profile of novel SERM indicates potential in both osteoporosis and endometriosis

Inhibitors of proteases such as cathepsin K and methods of use

Oligobenzimidazoles discovered by Aventis to be useful for DNA transfection

Orally active antifungal agents patented by Toagosei

Novel antiallergic agents in the Taisho pipeline

Chemokine antagonists claimed for wide series of conditions in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...